Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.

Michele CorrealeAdriana MallardiLucia TricaricoPietro MazzeoArmando FerrarettiClaudia DiellaValentina RomanoGiuseppina MerollaMassimo IacovielloMatteo Di BiaseNatale Daniele Brunetti

Published in: Acta cardiologica (2021)

Treatment with sacubitril/valsartan in patients with systolic dysfunction is associated with an improvement in LVEF in a real world scenario. Smaller LV volumes are associated with better reverse LV remodelling.

Keyphrases

left ventricular
ejection fraction
aortic stenosis
heart failure
blood pressure
hypertrophic cardiomyopathy
acute myocardial infarction
cardiac resynchronization therapy
oxidative stress
mitral valve
stem cells
left atrial
coronary artery disease
bone marrow
cell therapy